Terms: = Ovarian cancer AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS AND Treatment
31 results:
1. The impact of lymphadenectomy on ovarian clear cell carcinoma: a systematic review and meta-analysis.
Liu Y; Geng F; Zhang H; Xue J; Chu R
World J Surg Oncol; 2024 Jan; 22(1):37. PubMed ID: 38287354
[TBL] [Abstract] [Full Text] [Related]
2.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract] [Full Text] [Related]
3. Homologous Recombination Deficiency: cancer Predispositions and treatment Implications.
Toh M; Ngeow J
Oncologist; 2021 Sep; 26(9):e1526-e1537. PubMed ID: 34021944
[TBL] [Abstract] [Full Text] [Related]
4. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
5. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract] [Full Text] [Related]
6. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, ovarian, and Fallopian Tube cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract] [Full Text] [Related]
7. Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study.
Laasik M; Kemppainen J; Auranen A; Hietanen S; Grénman S; Seppänen M; Hynninen J
Cancer Imaging; 2019 May; 19(1):27. PubMed ID: 31142357
[TBL] [Abstract] [Full Text] [Related]
8. Elective and Onco-fertility preservation: factors related to IVF outcomes.
Cobo A; García-Velasco J; Domingo J; Pellicer A; Remohí J
Hum Reprod; 2018 Dec; 33(12):2222-2231. PubMed ID: 30383235
[TBL] [Abstract] [Full Text] [Related]
9. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Shaalan W; Elemam D; Mansour H; Melis M; Malik E; Soliman AA
J Gynecol Oncol; 2018 Jul; 29(4):e47. PubMed ID: 29770618
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of blm promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.
Birkbak NJ; Li Y; Pathania S; Greene-Colozzi A; Dreze M; Bowman-Colin C; Sztupinszki Z; Krzystanek M; Diossy M; Tung N; Ryan PD; Garber JE; Silver DP; Iglehart JD; Wang ZC; Szuts D; Szallasi Z; Richardson AL
Ann Oncol; 2018 Apr; 29(4):903-909. PubMed ID: 29452344
[TBL] [Abstract] [Full Text] [Related]
11. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract] [Full Text] [Related]
12. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
[TBL] [Abstract] [Full Text] [Related]
13. Olaparib for Maintenance treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive ovarian, Fallopian Tube and Peritoneal cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
van Meurs HS; van der Velden J; Buist MR; van Driel WJ; Kenter GG; van Lonkhuijzen LR
Acta Obstet Gynecol Scand; 2015 Nov; 94(11):1269-75. PubMed ID: 26230362
[TBL] [Abstract] [Full Text] [Related]
15. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer.
Matsushita Y; Yokoyama Y; Yoshida H; Osawa Y; Mizunuma M; Shigeto T; Futagami M; Imaizumi T; Mizunuma H
J Ovarian Res; 2014 Nov; 7():107. PubMed ID: 25424877
[TBL] [Abstract] [Full Text] [Related]
16. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.
Bjørnholt SM; Kjaer SK; Nielsen TS; Jensen A
Hum Reprod; 2015 Jan; 30(1):222-31. PubMed ID: 25376453
[TBL] [Abstract] [Full Text] [Related]
17. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract] [Full Text] [Related]
18. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
Raja FA; Counsell N; Colombo N; Pfisterer J; du Bois A; Parmar MK; Vergote IB; Gonzalez-Martin A; Alberts DS; Plante M; Torri V; Ledermann JA
Ann Oncol; 2013 Dec; 24(12):3028-34. PubMed ID: 24190964
[TBL] [Abstract] [Full Text] [Related]
19. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J; Sun Z; Smith I; Price KN; Thürlimann B; Ejlertsen B; Bonnefoi H; Regan MM; Goldhirsch A; Coates AS;
Breast Cancer Res Treat; 2012 Jan; 131(1):295-306. PubMed ID: 21892704
[TBL] [Abstract] [Full Text] [Related]
20. 99mTc-MAA/ 90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization.
Ahmadzadehfar H; Sabet A; Muckle M; Wilhelm K; Reichmann K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1281-8. PubMed ID: 21359611
[TBL] [Abstract] [Full Text] [Related]
[Next]
